Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

What Role do Urgent Care Centers Play in Headache Management? A Quality Improvement Study of Select Urgent Care Facilities
Headache
Headache Posters (7:00 AM-5:00 PM)
096

To conduct a survey of urgent care (UC) centers to determine the type of care available for patients presenting with a chief complaint of acute headache.

Migraine affects more than 40 million Americans. Patients with acute migraine often seek urgent medical care to treat pain and associated symptoms that do not respond to therapeutic options at home. It is estimated that the majority of visits to the Emergency Department (ED) for headache can be accounted for by migraine patients. UC centers may be more suitable for evaluation and treatment of such patients.  There is little data on how headache is evaluated in UC settings and what types of treatments are available. 

Information was collected via a cross-sectional survey, including UC staffing (e.g. number and backgrounds of staff, hours of operation), average length of UC visits for headache, treatments and tests available for patients presenting with headache, and disposition including to the ED.  

A total of 10 UC programs (which included 61 UC sites) were surveyed.  The vast majority (8/10; 80%) had diagnostic testing onsite for headache evaluation. A small majority (6/10; 60%) had the American Headache Society recommended intravenous medications for acute migraine available. Half (5/10) had a headache protocol in place. The majority (6/10; 60%) had no follow up policy after UC discharge.

UC centers have the potential to provide expedited, affordable and cost-effective care for patients presenting for the evaluation and treatment of headache. However, considerable variability exists amongst UCs in their clinical approach to acute headaches. More studies are needed, along with the development of protocols and professional partnerships to help guide the evaluation, triage, and treatment of patients with acute headache in UC settings.

Authors/Disclosures
Annika Ehrlich, DNP, FNP-C, AQH, CNRN (UCSF Headache Center)
PRESENTER
Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Abbvie Pharmaceuticals. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pharmamark. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Focus MedEd. Dr. Ehrlich has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eNeura. Dr. Ehrlich has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Axome Therapeutics. Dr. Ehrlich has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Ehrlich has received personal compensation in the range of $5,000-$9,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Pacific. Dr. Ehrlich has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurology Advanced Practice Providers. Dr. Ehrlich has a non-compensated relationship as a Board President with Alliance for Headache Disorders Advocacy that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Ehrlich has a non-compensated relationship as a Board President with The Headache Alliance that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Ehrlich has a non-compensated relationship as a Advanced Practice Provider Board Liaison with American Headache Society that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Dennique Khanns Dennique Khanns has nothing to disclose.
Jenny Guiracocha Jenny Guiracocha has nothing to disclose.
Fawad A. Khan, MD (Ochsner Health System) The institution of Dr. Khan has received research support from Amgen .
Ashhar Ali, DO, FÂé¶¹´«Ã½Ó³»­ (Henry Ford Health) Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Ali has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Ebsco.
Addie Peretz, MD (Stanford University) Dr. Peretz has nothing to disclose.
Larry "LC" Charleston IV, MD, MSc, FAHS, FANA, FÂé¶¹´«Ã½Ó³»­ (A NeuRaye Of Sunshine Publishing, LLC) Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma Pharmaceuticals. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for LinPharma. Dr. Charleston has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Haleon. Dr. Charleston has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. The institution of Dr. Charleston has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsome. Dr. Charleston has or had stock in Mi-Helper Inc..Dr. Charleston has a non-compensated relationship as a Associate Editor with Headache Journal: The Journal of Head and Face Pain that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Charleston has a non-compensated relationship as a Board Member with Clinical Neurological Society of America that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Charleston has a non-compensated relationship as a Chair, EDI Advisory Committee (Non-voting Board Member) with American Headache Society that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.
Laur Marius Birlea, MD, FÂé¶¹´«Ã½Ó³»­ Dr. Birlea has nothing to disclose.
Niranjan N. Singh, MD, FÂé¶¹´«Ã½Ó³»­ Dr. Singh has nothing to disclose.
Mia T. Minen, MD, FÂé¶¹´«Ã½Ó³»­ (NYULMC Neurology) The institution of Dr. Minen has received research support from NIH. Dr. Minen has received intellectual property interests from a discovery or technology relating to health care. Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a First Contact-Primary Care Advisory Board Member with American Headache Society . Dr. Minen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PCORI grant on migraine evidence based map for stakeholders with ECRI .